Character of meibomian gland dysfunction in patients with diabetic polyneuropathy with severe complications
DOI:
https://doi.org/10.31288/oftalmolzh201751520Keywords:
meibomian glands dysfunction, diabetic polyneuropathy, Schirmer’s test, contact meibography, meibomian gland secretionsAbstract
Background. Meibomian gland dysfunction (MGD) is a chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion. Diabetic polyneuropathy can be a cause of MGD.
Purpose: To improve the efficacy of diagnosis of MGD in patients with severe complications of diabetic polyneuropathy.
Materials and Methods: Standard ophthalmological examination, the Schirmer’s test before and 2 hours after eyelid compression, the Norn’s test, the OPI test, a compression test, an IVAD test, contact meibography with green filter were performed. Severe complications of diabetic polyneuropathy (N3 stage) were recorded in 25 patients (50 eyes). A control group consisted of 97 persons (194 eyes) without diabetes.
Results and Discussion: The Schirmer’s test was 2.7 times reduced in patients with N3 stage (4.83 mm) in comparison with that in the control group (12.82) (p<0.001). The Norn’s test was 4.8 times lower in patients with N3-stage (3.45 sec) than in patients without diabetes (9.48 sec) (p<0.001). The OPI test in patients with N3 stage was 1.9 times lower than that in the control group, (p<0.001). The Schirmer’s test in patients with N3 were 1.2 times higher after compression than before it (p<0.05). According to meibography, in patients with N3, loss area of the meibomian glands corresponded to stage 4.
Conclusions: The patients with stage N3 had MGD stage 3 (44 %) and 4 (40 %), while the first stage of MGD was not identified in any patient.
References
1. Blackie CA, Korb DR. The diurnal secretory characteristics in individual meibomian glands. Cornea. 2009;29:34-38. https://doi.org/10.1097/ICO.0b013e3181ac9fd0
2. Blackie CA, Korb DR. Recovery time of an optimally secreting meibomian gland. Cornea. 2009;28:293-297. https://doi.org/10.1097/ICO.0b013e31818913b4
3. Bron AJ, Benjamin L, Snibson G. Meibomian gland disease. Classification and grading of lid changes. Eye. 1991;5:395-411. https://doi.org/10.1038/eye.1991.65
4. Boulton JM, Malik RA, Arezzo JC. Diabetic Somatic Neuropathies. Diabetes Care. 2004;27(6):1458-86. https://doi.org/10.2337/diacare.27.6.1458
5. Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J. Clinic. Investigation. 2003;111:431-3.https://doi.org/10.1172/JCI200317863
6. Foulks G, Bron A. A clinical description of meibomian gland dysfunction. Ocul Surf. 2003;107-26.
https://doi.org/10.1016/S1542-0124(12)70139-8
7. Jester JV, Nicolaides N, Smith RE. Meibomian gland studies: histologic and ultrastructural investigations. Invest Ophthalmol Vis Sci. 1981;20:537-47.
8. Kelly K Nichols. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. IOVS, Special Issue. 2011;52 (4).https://doi.org/10.1167/iovs.10-6997a
9. Kozak I, Bron AJ, Kucharova K. Morphologic and volumetric studies of the meibomian glands in elderly human eyelids. Corne. 2007;26:610-4.https://doi.org/10.1097/ICO.0b013e318041f0d2
10. Nelson JD, Shimazaki J, Benitez-del-Castillo JM et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011;52:1930-7.https://doi.org/10.1167/iovs.10-6997b
11. Ousler GW 3rd1, Hagberg KW, Schindelar M, Welch D, Abelson M. The Ocular Protection Index. Cornea. 2008;Jun; 27(5):509-13.https://doi.org/10.1097/ICO.0b013e31816583f6
12. Pflugfelder SC, Tseng S, Sanabria O et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea. 1998;17:38-56.https://doi.org/10.1097/00003226-199801000-00007
13. Pult H Meiboscale. Dr Heiko Pult. Optometry & Vision Research. 2015; Accessed February 10.https://doi.org/10.1016/j.clae.2014.11.112
14. Tomlinson A, Bron AJ, Korb DR et al. The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. Invest Ophthalmol Vis Sci. 2011;52:2006-49.https://doi.org/10.1167/iovs.10-6997f
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 П. А. Бездітко, Л. І. Івженко
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
